A Critical Look at Medication Management Issues in Alzheimer’s Disease

R. Ron Finley, B.S. Pharm., R.Ph, CGP
Lecturer (Emeritus) and Assistant Clinical Professor,
UCSF School of Pharmacy
Clinical Pharmacist, UCSF Memory and Aging Center-
Alzheimer’s Research Center

Educational Objectives

1. Define the role for cholinesterase inhibitors in the management of Alzheimer’s disease, Lewy Body dementia, Frontal Temporal Lobe dementia.
2. Name three common side effects of atypical antipsychotic drugs.
3. Construct a pharmacological treatment plan for a 77-year-old patient diagnosed with Alzheimer’s disease and hallucinations.
4. Describe the role for antipsychotic, antidepressant, mood stabilizers and benzodiazepines in the management of psychiatric behavior problems related to Alzheimer’s disease.
5. Cite three potential drug or disease interactions with cholinesterase inhibitors.

Disclosures

- Pfizer  Speakers Bureau
- Forest  Speakers Bureau
- Novartis  Speakers Bureau
- Rx Consultant  Associate Editor
- WindChime  Consultant
- HGA HealthCare Consultant
- Elder Care Specialist Consultant

Risk Factors Linked to AD

- Over 65 years of age and increases with age
- female
- Head injury
- Factors associated with DM, HTN, CVD
- Genetic: family history, specific chromosome mutations
- History of heavy cigarette smoking

The Many Faces of Dementia

- Alzheimer’s Disease
- Vascular: Multi-infarct
- Frontal Temporal Lobe dementia (FTD) and Pick’s disease
- Lewy Body Dementia
- Progressive Supranuclear Palsy
- Corticobasal Degeneration
- Primary Progressive Aphasia
- Huntington’s disease
- Dementia Associated with Parkinson’s, AIDS etc.
- Creutzfeldt-Jakob
Basic History of Illness
- **Lewy Body Dementia**
  - Hallucinations, Parkinsonism, Visual Spatial +/-
- **Frontotemporal Dementia**
  - Changes in personality, lack of impulse control
  - Dietary changes, compulsive behavior, (-) empathy
- **Vascular Dementia**
  - Progressive memory impairment, relatively rapid onset
  - History of DM, HTN, CVA, CAD

Basic History cont.
- **Alzheimer’s Disease**
  - Development of multiple cognitive deficits manifested by both memory impairment and 1 or more of the following cognitive disturbances:
    - aphasia, apraxia, agnosia, or disturbance in executive functioning.
  - *DSM IV-R*

Clinical Disease Progression

Pathophysiologic Hypothesis of AD

Goals of Therapy

Take a Complete Medication History
- Prescription Drugs
- Non-Prescription Drugs (ibuprofen, aspirin, etc.)
- Alternative treatments (vitamins, herbals, etc.)
- Social Drugs (alcohol, nicotine, caffeine)
- “Other Social Drugs” (marijuana, cocaine, etc.)
- Immunizations (influenza, pneumonia, etc.)
- Allergies (drugs, foods, etc.)
- What works, what doesn’t (e.g., pain meds)
- Medication Adherence
#1 “I only have two glasses of wine with dinner”

#2 “I only have a cocktail at social gatherings”

#3 “I don’t drink”

- Question
  - How large are the glasses?
  - Tell me about your social gatherings
  - Did you ever drink alcohol?

GH 73 year old male retired chemical physicist with a recent diagnosis of mild Alzheimer’s Disease

- CC: GH reports “I have no get up and go”. Spouse reports, ”He was very anxious, even before the AD diagnosis. We would like to start the Alzheimer’s medication”
- BP 120/80 HR 72 MMSE: 24 GDS: 2/30
- ADLs/IADLs: unable to select clothes, dresses with assistance, can no longer shop for groceries, needs assistance in preparing meals.
- Meds: Atenolol 25 mg daily, HCTZ 25 mg daily, alprazolam 0.25 mg orally four times daily
- OTC: ASA 81 mg daily, Huperzine A 200 mcg twice daily, Mind Matrix, 3 tablets daily (started 7 days ago)
RX galantamine ER 8 mg po once daily in the AM
- "I have severe nausea and diarrhea"
- "My anxiety has suddenly greatly increased"
- "I seem to be bruising much more than usual."
- "This new medicine you prescribed has terrible side effects" "Can I stop it?"

Drugs and Cognitive Impairment
- Common cause of potentially reversible cognitive impairment
- Demented patients are particularly prone to delirium from drugs
- Benzodiazepines, ETOH,
- Anticholinergic drugs are common offenders (TCAs, diphenhydramine, many others)
- Other offenders cimetidine, ranitidine, famotidine, steroids

Additional Anticholinergics
- Nortriptyline
- Paroxetine
- Olanzapine
- Hydroxyzine
- Cetirizine (Zirtec)
- Doxylamine (Unisom)
- Chlorpheniramine
- Brompheniramine

### Cholinesterase Inhibitors

<table>
<thead>
<tr>
<th>Year</th>
<th>1993</th>
<th>1996</th>
<th>2000</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Drug</strong></td>
<td>Tacrine</td>
<td>Aricept</td>
<td>Exelon</td>
<td>Razadyne</td>
</tr>
<tr>
<td><strong>Action</strong></td>
<td>reversible</td>
<td>reversible</td>
<td>Pseudo irreversible</td>
<td>reversible</td>
</tr>
<tr>
<td><strong>Class</strong></td>
<td>Acridine</td>
<td>Piperidine</td>
<td>Carbamat</td>
<td>Phenanthrene alkaloid</td>
</tr>
<tr>
<td><strong>AchE</strong></td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td><strong>BuChE</strong></td>
<td>yes</td>
<td>minimal</td>
<td>yes</td>
<td>minimal</td>
</tr>
</tbody>
</table>

### Donepezil Summary
- Donepezil (5 and 10 mg and 23 mg SR) may improve cognition and global function in patients with mild, moderate and severe AD
- Long-term efficacy is maintained for up to 50 weeks in select patients
- ADL may be partially maintained by donepezil
- Donepezil is generally safe and generally well tolerated

### Rivastigmine Summary
- Rivastigmine (6–12 mg/day or 4.6 to 9.5 mg/day patch) may improve cognition and global function in patients with mild-to-moderate AD
- Positive effects on ADL have been observed in some studies
- Rivastigmine is generally safe and well tolerated, although cholinergic side effects occur at high doses*
  - “fewer side effects with patch

### Galantamine (Razadyne®) Summary
- Galantamine (16 to 24 mg/day) Competitive inhibition of acetylcholinesterase
- Allosteric modulation of presynaptic and postsynaptic nicotinic receptors
- Galantamine may improve aspects of AD (e.g., cognition, behavior, function)
- Galantamine is generally well tolerated
- galantamine can be purchased as an herbal OTC
- Dose in Moderate Renal Impairment: 16 mg/ day

### Cholinesterase Inhibitors and Neuropsychiatric Symptoms*

<table>
<thead>
<tr>
<th>Source</th>
<th>N</th>
<th>Medication</th>
<th>Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morris et al</td>
<td>408</td>
<td>metrifonate</td>
<td>168</td>
</tr>
<tr>
<td>Dubois et al</td>
<td>605</td>
<td>metrifonate</td>
<td>168</td>
</tr>
<tr>
<td>Raskind et al</td>
<td>264</td>
<td>metrifonate</td>
<td>162</td>
</tr>
<tr>
<td>Raskind et al</td>
<td>978</td>
<td>galantamine</td>
<td>150</td>
</tr>
<tr>
<td>Rockwood et al</td>
<td>386</td>
<td>galantamine</td>
<td>90</td>
</tr>
<tr>
<td>Farlow et al</td>
<td>468</td>
<td>tacrine</td>
<td>84</td>
</tr>
<tr>
<td>Knapp et al</td>
<td>653</td>
<td>tacrine</td>
<td>210</td>
</tr>
<tr>
<td>Mollier et al</td>
<td>181</td>
<td>physostigmine</td>
<td>168</td>
</tr>
<tr>
<td>Zemian et al</td>
<td>309</td>
<td>velnacrine</td>
<td>42</td>
</tr>
<tr>
<td>Wemblad et al</td>
<td>226</td>
<td>donepezil</td>
<td>365</td>
</tr>
<tr>
<td>Jann</td>
<td>395</td>
<td>metrifonate</td>
<td>42</td>
</tr>
<tr>
<td>Becker</td>
<td>180</td>
<td>metrifonate</td>
<td>180</td>
</tr>
</tbody>
</table>

* tacrine and metrifonate studies*
Dosing Tips

- Nausea or Diarrhea Reduce dose and restart titration
- Titrate slowly
- Do not increase donepezil 10 mg daily abruptly to 23 mg dose.
- Divide dose (twice daily)
- GI SE? Consider starting memantine first
  - Titrate memantine up to max dose and then start cholinesterase inhibitor

Drug Interactions: AChEi

- Highly Anticholinergic Drugs
  - Belladonna Alkaloids
  - Tricyclic Antidepressants
  - First generation Antihistamines
  - Many skeletal muscle relaxants
  - Drugs to Tx urinary incontinence
  - Many Antipsychotic Drugs
  - Some antiarrhythmics (disopyramide)

Drug Interactions: AChEi’s

- Succinylcholine-type or cholinergic agonists
- Ketoconazole*
- Quinidine*
- Erythromycin*
- Paroxetine*
- Cimetidine*

* Either not clinically significant or unknown clinical significance

Optimizing AChEi Drug Therapy

- Do not expect immediate response
- Counsel patient-caregivers on expectations.
- Monitor medication adherence
- A six month trial
- Consider adding memantine
- Titrate to maximal tolerated dose
- Avoid anticholinergic drug interactions

AChEi Side Effects

- Nausea and/or Vomiting
- Diarrhea
- Disturbing Dreams
- Muscle cramps or pain
- Syncope
- Hypomania
- Weight loss
- Surgical Issues - interactions
Contraindications* and Precautions for AChEi’s

- Hypersensitivity to the ACEhI*
- Cardiac Conduction Conditions
- Symptomatic Bradycardia
- Severely Impaired Renal or Hepatic function

Pros and Cons of AChEi Therapy

**Pro**
- Some patients will benefit, better results in LBD vs AD
- May reduce need for psychoactive drugs
- Opportunity to improve ADL’s and IDL’s
- Reduction in caregiver time
- Reduction in Apathy, improved social awareness/interaction, improve ADLS

**Cons**
- Side effects may be troublesome
- Efficacy is variable
- Memory may not improve
- Costly
- Adds to “Medication Burden” thus increasing risk for nonadherence

Memantine

- Memantine—NMDA receptor antagonist
  - Improvement in patients with moderate to severe AD and possible benefits in VaD
  - Recent phase III trials (AD) indicate significant improvement compared with placebo
  - Patients with moderately severe and severe AD benefited the most
  - Clinical trial: memantine+donepezil was positive

Memantine Studies: Moderate to Severe AD

  - N181 completed study duration 28 weeks
    - ADCS-ADL*: P 0.02, CIBIC* 0.06, SIB: P 0.001
    - NPI, MMSE, GDS / P value > 0.06
  - Van Dyck et al: AD Assoc Disorders2007;21:2
    - N350 in a 24 week trial
    - SIB, ADCS-ADL, CIBIC-Plus,NPI showed no benefit at week 24.

  "In conclusion, this efficacy and safety study of memantine monotherapy for patients with moderate-to-severe AD did not demonstrate statistically significant treatment benefit at study end point on any primary or secondary outcome measure."

Memantine Treatment in Patients with Moderate to Severe Alzheimer’s Disease Receiving Donepezil

randomized, double-blind, placebo controlled
N=404  24 weeks
- SIB P<.001
- ADCS-ADL19  p=0.03
- CIBIC-Plus p= 0.03
- NPI p=  0.01
- Mean dose of donepezil 9.25 and 9.49 mg/d
- Side effects reported: 78% memantine vs 72% P

PN Tariot, MR Farlow, GT Grossberg, S McDonald, I Gergel for the Memantine Study Group. JAMA 2004;291:317
Memantine for AD

- Improvement in patients with moderate to severe AD and possible benefits in VaD1-2
- Patients with moderately severe and severe AD benefited the most1-2
- Evidence for Efficacy in Mild AD is Lacking
- Clinical trial: memantine + donepezil was positive1
- Clinical trial: memantine + rivastigmine was positive2

V aD=vascular dementia.


Memantine Dosing

- Week #1
  - Start memantine 5 mg po each morning
- Week #2
  - Increase dose to 5 mg po AM and PM
- Week #3
  - Increase dose to 10 mg AM and 5 mg PM
- Week #4
  - Increase dose to 10 mg AM and 10 mg PM
- Week #5
  - Maintain dose at 10 mg AM and 10 mg PM

Memantine Drug Interactions

- Carbonic anhydrase inhibitors
  - Alkalization of urine (decreased clearance)
  - Change in diet (vegetarian) may also increase urinary pH
  - Alkalizing agents, such as sodium bicarbonate
  - Ascorbic acid may acidify the urine, increasing excretion

Memantine Dosing in Patients With Renal Impairment

- Estimated creatinine clearance 5 to 29 mL/minute
- Target dose of 5 mg po twice daily
- Ebixa (memantine) in Europe is Dosed Once daily *
  *http://www.ebixa.com/prescribing_information/

Memantine Treatment in Patients with Moderate to Severe Alzheimer’s Disease Already Receiving Donepezil

Randomized, double-blind, placebo controlled
N=404 24 weeks

- SIB P< .001
- ADCS-ADL + p=.03
- CIBIC-Plus p=.03
- NPI p=.01
- Mean dose of donepezil 9.25 and 9.49 mg/d
- Side effects reported: 78% memantine vs 72% P

198 192 190 185 181 171 198
196 194 180 169 164 153

Memantine + Donepezil Produced Sustained Improvement in Cognition Above Baseline Compared With Donepezil Alone


Results: Cognition—SIB

Mean Change From Baseline in SIB Score

Week 0 4 8 12 16 20 24
Mean Change From Baseline in SIB Score

Week 0 4 8 12 16 20 24
Memantine+Donepezil
Memantine
Donepezil

Medical Foods

Axona

Brief Thoughts

Managing Psychiatric Behavioral issues related to Alzheimer’s disease and other dementia.

Patterns of Behavioral Disturbance

Metaphors or Syndromes

- Depression
- Agitation
- Psychosis
- Anxiety

Step #1

- Document and evaluate behavior
- Is behavior precipitated by an event?
- Determine if behavior poses a hazard
- Assess behavior for possible non drug Tx
- Is behavior amenable to drug therapy?
- Determine pros and cons of drug Tx
- Select least hazardous drug
- Set goals and monitoring guidelines and date to review need for continued drug therapy.

Step #2

- Repeat Step #1

Drugs used to Treat Behavior*

- Cholinesterase Inhibitors
- Antipsychotics (typical and atypical)
- Benzodiazepines (anxiolytics)
- Anti-seizure (Mood Stabilizers)
- Antidepressants
- Beta Blockers
- Hormonal
- Psychostimulants
- Trazodone

* No Medications are FDA approved for the treatment of psychiatric behavioral conditions associated with a dementia.
Antipsychotic Drugs

Typical Antipsychotic
- A. chlorpromazine
- B. thioridazine
- C. loxapine
- D. perphenazine
- E. fluphenazine
- F. haloperidol

And Others.

Atypical Antipsychotics
- A. clozapine
- B. risperidone
- C. olanzapine
- D. quetiapine
- E. ziprasidone
- F. aripiprazole
- G. paliperidone

And Others.

Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials.
- Olanzapine: 1.3% (15/1178)
- Placebo: 0.4% (2/478)

CMAJ. April 27, 2004; 170 (9)

Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials
- Risperidone: 4% (29/764)
- Placebo: 2% (7/466)

CMAJ. November 6, 2002; 167:11

Antidepressants

Monoamine oxidase inhibitors
- phenelzine, tranylcypromine, selegiline (Emsam®)

Tricyclics
- amitriptyline, nortriptyline, imipramine, desipramine, trimipramine, doxepin, clomipramine, protriptyline

Tetracyclics
- maprotiline, amoxapine

*selegiline (Emsam®) transdermal patch

SSRI’s: fluoxetine*, paroxetine*, sertraline, citalopram, escitalopram

Bupropion
Mirtazepine
SNRI’s: Venlafaxine, Desvenlafaxine Duloxetine, Milnacipran

Trazodone, Nefazodone, Vilazodone)
*Generally not optimal choice
Paroxetine and Fluoxetine
- Acetaminophen with codeine
- Aripiprazole
- Risperidone
- Nortriptyline
- Metoprolol
- NSAIDS
- Tamoxifen
- Warfarin (?)

References: http://www.fda.gov/CDER/drug/drugReactions/testQuestions.htm
The Top 100 Drug Interactions, 2008 Edition, Hansten and Horn, Hellman publications, Freeland WA
Drug Interactions. LexiComp.com

SSRI’s for Behavior in AD
- Effect of a Serotonin Reuptake Inhibitor on Irritability, Apathy, and Psychotic Symptoms in Patients With Alzheimer’s Disease
  - “Conclusions: The use of citalopram was associated with greatly reduced irritability with- out sedation in a group of behaviorally disturbed patients with AD.”

A Double-Blind Comparison of Citalopram and Risperidone for the Treatment of Behavioral and Psychotic Symptoms Associated With Dementia
- Conclusion: No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia. These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alter- natives to antipsychotics for the treatment of agitation or psychiatric symptoms associated with dementia.

Comparison of Citalopram, Perphenazine, and Placebo for the Acute Treatment of Psychosis and Behavioral Disturbances in Hospitalized, Demented Patients
- Conclusions: Citalopram was found to be more efficacious than placebo in the short-term hospital treatment of psychotic symptoms and behavioral disturbances in nondepressed, demented patients.

Valproate (VA) in Dementia
- Cochrane Review: December 2010
  - The new meta-analysis of pooled results showed no improvement of agitation among valproate treated patients, compared with controls, and showed an increase in adverse events (falls, infection, gastrointestinal disorders) among valproate treated patients.
  - Authors’ conclusions:
    - The updated review corroborates the earlier findings that valproate preparations are ineffective in treating agitation among demented patients, and that valproate therapy is associated with an unacceptable rate of adverse effects. More research on the use of valproate preparations for agitation of people with dementia is needed. On the basis of current evidence, valproate therapy cannot be recommended for management of agitation in dementia.
  - Plain language summary: No evidence of efficacy of valproate preparations for treatment of agitation in people with dementia

Benzodiazepines
- Antianxiety
- Antispasmodic
- Anti Seizure Activity
- Sedative/hypnotic
Equivalent Doses of BDZ’s

- Lorazepam 1 mg = 5 to 10 mg of Diazepam =
- Alprazolam 1 mg =
- Clonazepam 0.5 mg =
- Oxazepam 10 mg =
- Chlordiazepoxide 25 mg

- Psychotropic Drug Handbook, Lippincott

BDZ Side Effects to Watch For

- Impaired Psychomotor Skills
- Impaired Memory
- Falls
- Withdrawal Symptoms
- Additive CNS depressant to ETOH, etc.

Other Anxiolytic Medications

- Buspirone (Buspar®)
- Barbiturates (phenobarbital, butalbital)
- Meprobamate (Miltown® Equanil®)
- ETOH

Behavior

- Non Drug
- Non Drug
- Trazodone (Sleep)
- Antipsychotics
- Antidepressants
- Mood Stabilizers
- Benzodiazepines

Summary: Something to keep in mind

Who are you?

The Caterpillar and Alice looked at each other for some time in silence; at last the Caterpillar took the hookah out of its mouth, and addressed her in a languid, sleepy voice. “Who are you?” said the Caterpillar. A rather shyly, “I — I hardly know, sir, just at present — at least I know who I was when I got up this morning, but I think I must have been changed several times since then.” “What do you mean by that?” said the Caterpillar sternly. “Explain yourself!” “I can’t explain myself, I’m afraid, sir,” said Alice, “because I’m not myself, you see.”

Ch. 5 – Advice from a Caterpillar, Alice in Wonderland, L. Carroll

Quote

Where are you going?

How will you get there?

How do you know when you have arrived?
Questions?
Ron Finley, B.S. Pharm, R.Ph., CGP
finleyr@pharmacy.ucsf.edu
(additional references available upon request)

Select References

Select References
- FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Available at: http://www.fda.gov/cder/drug/advisory/antipsychotics.htm
- Street JS et al. Olanzapine. Archives of Gen Psychiatry 2000;57:968

References
- Research: alzforum.org